Anheuser-Busch InBev SA/NV (BUD) Research
Anheuser-Busch InBev SA/NV (AB InBev) is a global beverage giant involved in the manufacturing, marketing, and retailing of a wide variety of beers, other alcoholic drinks, and soft drinks across the world. The company manages an expansive collection of around 500 beer labels. Its most prominent and globally recognized brands include Budweiser, Corona, and Stella Artois. Additionally, its portfolio features well-known names such as Beck's, Hoegaarden, Leffe, and Michelob Ultra, alongside a host of other popular brands like Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol. Established in 1366, AB InBev's corporate headquarters are situated in Leuven, Belgium.
Market snapshot
- Symbol
- BUD
- Price
- $80.74
- Day change
- +0.07%
- Market cap
- $155.9B
- P/E ratio
- 21.97x
- 52-week range
- 56.97-84.46
- Sector
- Consumer Defensive
- Industry
- Beverages - Alcoholic
- Next earnings
- in 1 month
- Analyst price target
- $89.00
Recent news
- Move over, seltzer. Non-carbonated drinks are taking the spotlight
The growth of seltzer and other carbonated drinks has slowed as fizz-free options grab shelf space and attention. Non-carbonated alcoholic drinks like Surfside and BeatBox are stealing "share of throat" from hard seltzers, particularly among Gen Z.
- How AB InBev Stopped Its Three-Year Slide
A focus on top-selling brands and beer alternatives helped the mega-brewer claim volume-based growth, according to its marketing chief.
Peer companies
Recent insider activity
- BUSCH AUGUST A III — D-Return (34940 shares) on 2008-11-18
- BUSCH AUGUST A III — D-Return (100000 shares) on 2008-11-18
- BUSCH AUGUST A III — D-Return (5000 shares) on 2008-11-18
- BUSCH AUGUST A III — D-Return (2628 shares) on 2008-11-18
- BUSCH AUGUST A III — D-Return (897954 shares) on 2008-11-18
Open Anheuser-Busch InBev SA/NV (BUD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.